Tegoprazan vs Lansoprazole for Healing Bleeding Peptic Ulcers
Official title: A Double-Blind, Double-Dummy, Randomized Controlled Trial Comparing 14-Day Tegoprazan Versus Lansoprazole Therapy for Endoscopic Ulcer Healing in Patients With Bleeding Peptic Ulcers
Run by Universitas Indonesia · NCT07708545 · Data updated 2026-11-12
This trial tests whether tegoprazan heals bleeding peptic ulcers faster than lansoprazole over 14 days in adults with upper GI bleeding in Indonesia.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 162 (estimated) |
| Sponsor | Universitas Indonesia Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Tangerang, Banten and 2 other locations) |
| Status | Recruiting |
| Started | August 6, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | February 28, 2027 |
| Registry record updated | August 21, 2026 |
| Trial ID | NCT07708545 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years and older with endoscopically confirmed bleeding peptic ulcers eligible for 14 days of tegoprazan or lansoprazole therapy.
✕Probably not a fit
Patients not showing ulcer healing or who have non-peptic causes of bleeding may not benefit from this comparison.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 randomized trial compares tegoprazan to lansoprazole for healing bleeding peptic ulcers. Eligible adults with upper GI bleeding receive initial stabilization, high-dose acid suppression, and gastroscopy with possible endoscopic therapy, followed by daily dosing of either tegoprazan or lansoprazole for 14 days. The primary goal is to determine which drug achieves better ulcer healing after two weeks. Endpoints include endoscopic healing at 14 days and safety in this patient population. Study sites include hospitals in Jakarta, Tangerang, and Padang under Universitas Indonesia leadership.
Why it matters
Potential benefit: If tegoprazan proves superior, patients may experience faster ulcer healing and reduced risk of rebleeding.
How similar studies have gone: Direct head-to-head comparisons of tegoprazan and lansoprazole are limited, making this study relatively novel in the bleeding peptic ulcer setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects aged 18 years and over. * Subjects with upper gastrointestinal bleeding caused by peptic ulcers diagnosed by gastroscopy. * Willing to participate in the entire clinical study process, including: 1. . Fluid resuscitation and blood transfusion, if necessary, 2. . High-dose PPI therapy for 72 hours, 3. . Gastroscopy within 24 hours of hospital admission and endoscopic hemostatic therapy, if necessary, 4. . Lansoprazole 30 mg or tegoprazan 50 mg therapy for 14 days, 5. . Treatment for H. pylori infection if positive, 6. . Repeat gastroscopy after 14 days of treatment to assess the progress of therapy. Exclusion Criteria: * Subjects with a history of allergy to tegoprazan or lansoprazole * Subjects with a history of allergy to tegoprazan or lansoprazole. * Subjects with ulcers caused by gastric or duodenal cancer. * Subjects with comorbidities such as chronic kidney disease stage 3 or higher and decompensated liver cirrhosis. * Patients who are heavy alcohol drinkers and have used chemotherapy drugs, bisphosphonates, or potassium supplements in the past 2 weeks.
Where it's running
-
RSUD Balaraja
Tangerang, Banten, Indonesia Recruiting -
RSUPN Dr. Cipto Mangunkusumo
Jakarta Pusat, DKI Jakarta, Indonesia Recruiting -
RSUP Dr. M. Djamil
Padang, West Sumatra, Indonesia Recruiting
Study contacts
- Principal investigator: Hasan Maulahela, MD, PhD — Universitas Indonesia
- Study coordinator: dr. Hasan Maulahela, Sp.PD-KGEH, MD, PhD
- Email: aspendrhasanmaulahela@gmail.com
- Phone: +6281283602549
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing Tegoprazan and Lansoprazole for Treating Bleeding Peptic Ulcers
This study is testing whether tegoprazan works better than lansoprazole for healing bleeding peptic ulcers in patients from Indonesia.
-
Predicting Extubation Problems With Machine Learning
This study tests whether computer models can predict extubation failure in adults on ventilators in the ICU.
-
Structured swallowing exercises for nasopharyngeal cancer patients
This trial tests whether a structured swallowing exercise program improves swallowing and quality of life more than conventional swallowing exercises in adults with nasopharyngeal carcinoma.
-
Digital cognitive behavioral therapy for gambling disorder and family support
This pilot trial tests whether digital CBT for adults with gambling disorder, with optional online family support, works as well as traditional face-to-face CBT in Indonesia.
-
Hospital-based look at infants under 6 months with acute malnutrition
This study follows hospitalized infants under 6 months with acute malnutrition to see how common it is and how they grow during treatment.
-
Postoperative Care Pathways: PACU vs HCU in Elective Surgeries
This study looks at whether recovering in the PACU or the HCU after elective surgery affects how long patients stay in the hospital and how often they need a higher level of care afterward.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.